07:00 Tue 06 Oct 2020
OptiBiotix Health - Exclusive distribution agreement
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Exclusive distribution agreement with United Italian Trading Corporation (Pte) Ltd
Exclusive rights to CholBiomeX3 in
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd ("ProBiotix"), has entered into an exclusive distribution agreement with United Italian Trading Corporation (Pte) Ltd ("UITC") to distribute OptiBiotix's cholesterol reducing product, CholBiomeX3, in
UITC (https://uitc.com.sg) is an established pharmaceutical and medical device marketing and distribution company founded in
UITC has agreed to place an order for 5,000 boxes of CholBiomeX3 for delivery by the end of 2020 and increasing annual minimum order quantities to retain exclusivity.
This agreement is another example of the increasing number of pharmaceutical companies commercialising CholBiome® products into the high value GP, hospital and pharmacy markets.
For further information, please contact:
OptiBiotix Health plc |
|
|
Contact via Walbrook below |
|
|
finnCap (Broker) |
Tel: 020 7220 0500 |
|
|
Walbrook PR Ltd |
Mob: 07876 741 001 |
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE